IP Library › Granted Patent US 7,919,095
Granted Patent B2
US 7,919,095 · App. 11/882,751 · Granted Apr 5, 2011

Anti-IL-6 monoclonal antibodies

Assignee: Vaccinex, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,919,095
App. No.
11/882,751
Granted
Apr 5, 2011
Kind
B2
Abstract

The present invention provides novel monoclonal antibodies that bind specifically to IL-6. The antibodies of the invention comprise a variable heavy chain (VH) region selected from any of the VH regions disclosed herein as well as amino acid variants thereof, and/or a variable light chain (VL) region selected from any of the VL regions disclosed herein as well as amino acid variants thereof. The invention also provides methods of treating diseases and disorders associated with IL-6 expression and/or activity.

Claims (52)

1. An isolated monoclonal antibody comprising:

(a) a variable heavy chain region (VH) comprising:

(i) a VH-CDR1 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, and SEQ ID NO:55;

(ii) a VH-CDR2 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:97 and SEQ ID NO:101;

(iii) a VH-CDR3 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:62, SEQ ID NO:63, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, and SEQ ID NO:98; and

(b) a variable light chain region (VL) comprising:

(i) a VL-CDR1 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, SEQ ID NO:78, and SEQ ID NO:79;

(ii) a VL-CDR2 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:80, SEQ ID NO:81, SEQ ID NO:82, SEQ ID NO:83, SEQ ID NO:84, and SEQ ID NO:85;

(iii) a VL-CDR3 comprising an amino acid sequence selected from the group consisting of: SEQ ID NO:86, SEQ ID NO:87, SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, SEQ ID NO:95, and SEQ ID NO:96;

wherein said antibody binds specifically to an IL-6 antigen.

2. A pharmaceutical composition comprising the isolated monoclonal antibody of claim 1 and a pharmaceutically acceptable carrier.

3. The isolated monoclonal antibody of claim 1 , wherein said antibody inhibits IL-6-induced proliferation of murine B9 (ECACC) cells or human U266 myeloma cells at a level of 80% or greater inhibition.

4. The isolated monoclonal antibody of claim 1 , wherein said antibody binds specifically to IL-6, inhibiting the binding of IL-6 to its receptor at a level of 80% or greater inhibition.

5. The antibody of claim 1 , wherein said VH-CDR1 comprises the amino acid sequence of SEQ ID NO:54, said VH-CDR2 comprises the amino acid sequence of SEQ ID NO:101, and said VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73.

6. The antibody of claim 1 , wherein said VL-CDR1 comprises the amino acid sequence of SEQ ID NO:79, said VL-CDR2 comprises the amino acid sequence of SEQ ID NO:85, and said VL-CDR3 comprises the amino acid sequence of SEQ ID NO:95.

7. The antibody of claim 1 , wherein said VH-CDR1 comprises the amino acid sequence of SEQ ID NO:54, said VH-CDR2 comprises the amino acid sequence of SEQ ID NO:101, said VH-CDR3 comprises the amino acid sequence of SEQ ID NO:73, said VL-CDR1 comprises the amino acid sequence of SEQ ID NO:79, said VL-CDR2 comprises the amino acid sequence of SEQ ID NO:85, and said VL-CDR3 comprises the amino acid sequence of SEQ ID NO:95.

8. The antibody of claim 1 , wherein said VH comprises the amino acid sequence of SEQ ID NO:43 and said VL comprises the amino acid sequence of SEQ ID NO:36.

9. The antibody of claim 1 , wherein said antibody comprises a combination of CDRS selected from the group consisting of:

(a) the VH-CDR1 of SEQ ID NO:51, the VH-CDR2 of SEQ ID NO:56, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:76, the VL-CDR2 of SEQ ID NO:82, and the VL-CDR3 of SEQ ID NO:88;

(b) the VH-CDR1 of SEQ ID NO:51, the VH-CDR2 of SEQ ID NO:56, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:77, the VL-CDR2 of SEQ ID NO:83, and the VL-CDR3 of SEQ ID NO:89;

(c) the VH-CDR1 of SEQ ID NO:51, the VH-CDR2 of SEQ ID NO:56, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:78, the VL-CDR2 of SEQ ID NO:84, and the VL-CDR3 of SEQ ID NO:90;

(d) the VH-CDR1 of SEQ ID NO:51, the VH-CDR2 of SEQ ID NO:56, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(e) the VH-CDR1 of SEQ ID NO:51, the VH-CDR2 of SEQ ID NO:56, the VH-CDR3 of SEQ ID NO:98, the VL-CDR1 of SEQ ID NO:78, the VL-CDR2 of SEQ ID NO:84, and the VL-CDR3 of SEQ ID NO:90;

(f) the VH-CDR1 of SEQ ID NO:53, the VH-CDR2 of SEQ ID NO:58, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:75, the VL-CDR2 of SEQ ID NO:81, and the VL-CDR3 of SEQ ID NO:87;

(g) the VH-CDR1 of SEQ ID NO:53, the VH-CDR2 of SEQ ID NO:59, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:75, the VL-CDR2 of SEQ ID NO:81, and the VL-CDR3 of SEQ ID NO:87;

(h) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:75, the VL-CDR2 of SEQ ID NO:81, and the VL-CDR3 of SEQ ID NO:87;

(i) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:76, the VL-CDR2 of SEQ ID NO:82, and the VL-CDR3 of SEQ ID NO:88;

(j) the VH-CDR1 of SEQ ID NO:52, the VH-CDR2 of SEQ ID NO:57, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:74, the VL-CDR2 of SEQ ID NO:80, and the VL-CDR3 of SEQ ID NO:86;

(k) the VH-CDR1 of SEQ ID NO:52, the VH-CDR2 of SEQ ID NO:57, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:75, the VL-CDR2 of SEQ ID NO:81, and the VL-CDR3 of SEQ ID NO:87;

(l) the VH-CDR1 of SEQ ID NO:52, the VH-CDR2 of SEQ ID NO:57, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:76, the VL-CDR2 of SEQ ID NO:82, and the VL-CDR3 of SEQ ID NO:88;

(m) the VH-CDR1 of SEQ ID NO:51, the VH-CDR2 of SEQ ID NO:97, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:75, the VL-CDR2 of SEQ ID NO:81, and the VL-CDR3 of SEQ ID NO:87;

(n) the VH-CDR1 of SEQ ID NO:51, the VH-CDR2 of SEQ ID NO:97, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:76, the VL-CDR2 of SEQ ID NO:82, and the VL-CDR3 of SEQ ID NO:88;

(o) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(p) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:63, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(q) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:64, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(r) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:65, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(s) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:66, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(t) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ NO:60, the VH-CDR3 of SEQ ID NO:67, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(u) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:68, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(v) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:69, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(w) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:92;

(x) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:93;

(y) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:96;

(z) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:96;

(aa) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:73, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(bb) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:73, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:93;

(cc) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:60, the VH-CDR3 of SEQ ID NO:73, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:92;

(dd) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:101, the VH-CDR3 of SEQ ID NO:62, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(ee) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:101, the VH-CDR3 of SEQ ID NO:73, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:91;

(ff) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:101, the VH-CDR3 of SEQ ID NO:73, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:93;

(gg) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:101, the VH-CDR3 of SEQ ID NO:73, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:92; and

(hh) the VH-CDR1 of SEQ ID NO:54, the VH-CDR2 of SEQ ID NO:101, the VH-CDR3 of SEQ ID NO:73, the VL-CDR1 of SEQ ID NO:79, the VL-CDR2 of SEQ ID NO:85, and the VL-CDR3 of SEQ ID NO:96.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 20, 2007
From: SMITH, ERNEST S.; WANG, WEI
To: VACCINEX, INC.
Reel/Frame 020140/0566 →
Continuity (2)
Provisional Application 60835107 · Aug 3, 2006
Related Publication 20080075726A1 · Mar 27, 2008